UnitedHealth Group Beats Q1 2026 Estimates, Raises Profit Outlook UnitedHealth Group reported first-quarter earnings that exceeded Wall Street expectations for both revenue and earnings per share on Tuesday, April 21, …
Biotech and Pharmaceuticals
-
-
Merck to Acquire Terns Pharma for $6 Billion to Bolster Cancer Pipeline Pharmaceutical giant Merck & Co. announced Wednesday it is nearing a $6 billion all-cash acquisition of U.S. Biotech …
-
The Rising Cost of Menstrual Products and Consumer Response Inflation and evolving tariff policies are impacting household budgets, and one often-overlooked area of increased expense is menstrual products. Despite declining …
-
Lilly’s Retatrutide Shows Promise in Type 2 Diabetes Trial, Delivering Significant Weight Loss Eli Lilly and Company announced positive topline results from the TRANSCEND-T2D-1 Phase 3 clinical trial evaluating retatrutide, …
-
Eli Lilly Launches Zepbound KwikPen for More Convenient Weight Management Eli Lilly and Company announced on Monday the availability of a new delivery option for its blockbuster obesity drug, Zepbound …
-
Novo Nordisk on Monday said it is suing online telehealth provider Hims & Hers for mass marketing cheaper, unapproved copies of the drugmaker’s new Wegovy obesity pill and injections in …
-
Novo Nordisk shares jumped 8% Monday after Hims & Hers said it will pull its copycat weight-loss pill off the market. Novo Nordisk, maker of Wegovy, and the U.S. Food …
-
Novo Nordisk‘s shift from a market darling to a serious underperformer has set the stage for a transitional 2026 as the Danish drugmaker fights to regain investor confidence in its …
-
Novo Nordisk has had a tough year: a tumbling stock price resulting in the biggest leadership shakeup in the company’s 100-year history as investors turned thier back on the Danish …
-
the U.S. Food and Drug management on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, a landmark decision that health experts say could open up …